At present, this therapy has been applied to patients with immune-mediated inflammatory diseases (NCT04870203), and findings showed that the combination of Baricitinib and the TNF inhibitor improved treatment efficacy for RA patients without obvious acute adverse effects. The gene discussed is TNF; the disease is rheumatoid arthritis.